首頁 > 市場調查報告書 > 醫療設備

導管心血管設備

市場調查報告書

商品編碼

1620215

冠狀動脈支架市場：依類型、依材料類型、依最終用戶、按地區，2024-2031

Coronary Stent Market By Type (Bare-Metal Stents (BMS), Drug-Eluting Stents (DES)), By Material Type (Polymer-Based Stents, Metallic Stents), By End User (Cardiac Centers, Hospitals) And Region For 2024-2031

出版日期: 2024年10月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

冠狀動脈支架市場評估 - 2024-2031

全球冠狀動脈支架的需求正在穩步增長，這主要是由於心血管疾病盛行率的上升和支架技術的進步。心血管疾病仍然是全球死亡的主要原因，其影響因素包括久坐的生活方式、不健康的飲食、吸煙以及發達和發展中地區的人口老化。隨著冠狀動脈疾病盛行率的增加，對有效治療方案的需求也在增加，從而推動了冠狀動脈支架市場的發展。2023年市場規模將超過71.1億美元，2031年將達到約138.7億美元。

支架技術的創新，包括藥物洗脫支架和生物可吸收血管支架，使這些設備更安全、更有效，進一步推動了它們在醫學界的廣泛採用。對具有成本效益和高效的冠狀動脈支架的需求不斷增長，使得市場從 2024 年到 2031 年的複合年增長率為 8.71%。

冠狀動脈支架市場定義/概述

冠狀動脈支架是由金屬製成的小網管，用於治療向心臟供血的冠狀動脈狹窄或阻塞。它通常在經皮冠狀動脈介入治療 (PCI) 或血管成形術過程中植入。冠狀動脈支架旨在支撐動脈壁，恢復血流並降低胸痛、心臟病和其他與冠狀動脈疾病 (CAD) 相關的併發症的風險。冠狀動脈支架有多種類型，包括裸金屬支架、藥物洗脫支架（DES）和生物可吸收支架，每種支架在安全性、有效性和壽命方面都有獨特的優勢。

由於支架技術的進步、微創手術需求的增加以及 CAD 盛行率的增加，冠狀動脈支架顯示出前景。生物可吸收支架和基於奈米技術的支架等新創新有望透過減少再狹窄和血栓形成等併發症來改善長期預後。此外，隨著全球人口老化和醫療保健普及程度的提高，尤其是在新興地區，對冠狀動脈支架的需求將會增加，為市場創造新的成長機會。

心血管疾病（CVD）盛行率的上升會推動冠狀動脈支架市場嗎？

心血管疾病（CVD）盛行率的上升極大地推動了冠狀動脈支架市場的發展，這主要是由於對有效治療方案的需求不斷增長來管理和緩解冠狀動脈阻塞。根據世界衛生組織統計，心血管疾病每年導致全球 1,790 萬人死亡，疾病預防控制中心報告稱，冠心病影響著約 1,820 萬美國成年人，冠狀動脈支架的需求正在迅速增加。隨著醫療保健系統旨在降低與心血管疾病相關的發病率和死亡率，越來越多的患者需要先進且易於使用的支架解決方案，從而推動市場成長。

老年人口的增加正在推動冠狀動脈支架市場的發展。由於老化是冠狀動脈疾病的主要危險因素，老年人數量的增加直接增加了冠狀動脈支架的需求。據聯合國稱，到2050年，全球65歲及以上人口預計將達到15億，其中發展中地區增長最快。在歐盟，近 20% 的經皮冠狀動脈介入治療 (PCI) 是在 75 歲或以上的患者中進行的，這表明衰老與支架置入術增加之間存在明顯的關聯。

高成本會影響冠狀動脈支架市場的成長嗎？

冠狀動脈支架的高成本可能會影響冠狀動脈支架市場的成長。支架治療（尤其是先進的藥物洗脫支架）的成本可能會讓患者和醫療保健系統望而卻步，尤其是在預算有限且醫療保險有限的低收入和中等收入國家。這些成本也會影響保險費，減少支架治療的可及性，並減緩滲透率和市場成長，儘管人口老化和心血管疾病盛行率上升導致需求增加。

併發症的風險可能會影響冠狀動脈支架市場的成長。支架血栓形成、再狹窄和出血等併發症會帶來嚴重的健康風險，並可能導致額外的手術、醫療費用增加和患者猶豫。儘管支架技術的進步旨在最大限度地減少這些風險，但市場成長已經放緩，因為對這些潛在併發症的擔憂可能會促使醫療保健提供者考慮替代治療。

概述
北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 亞太其他地區
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲
中東/非洲
- 沙烏地阿拉伯
- 阿拉伯聯合酋長國
- 南非
- 其他中東和非洲

第9章全球冠狀動脈支架市場：競爭格局

概述
各公司市場排名
主要發展策略
公司產業足跡
公司區域足跡
王牌矩陣

第10章公司簡介

Abbott Laboratories
Boston Scientific
Medtronic
Terumo Corporation
B. Braun Melsungen
Cook Medical
Biosensors International
Biotronik, Johnson & Johnson
Meril Life Sciences

第11章主要進展

產品發佈/開發
併購
業務拓展
夥伴關係和聯盟

第12章附錄

相關報導

簡介目錄

Product Code: 10608

Coronary Stent Market Valuation - 2024-2031

The global demand for coronary stents has been steadily increasing, driven primarily by the rising prevalence of cardiovascular diseases and advancements in stent technology. Cardiovascular disease remains a leading cause of death worldwide, with contributing factors such as sedentary lifestyles, unhealthy diets, smoking, and aging populations in developed and developing regions. As the incidence of coronary artery disease rises, so does the need for effective treatment options, propelling the market for coronary stents. The market size surpass USD 7.11 Billion valued in 2023 to reach a valuation of aroundUSD 13.87 Billion by 2031.

Innovations in stent technology, including drug-eluting stents and bioresorbable vascular scaffolds, have made these devices safer and more effective, further supporting their increased adoption in the medical community. The rising demand for cost-effective and efficient coronary stent is enabling the market grow at aCAGR of 8.71% from 2024 to 2031.

Coronary Stent Market: Definition/ Overview

A coronary stent is a small, metal mesh tube used to treat narrowed or blocked coronary arteries, which supply blood to the heart. It is typically implanted during a procedure known as percutaneous coronary intervention (PCI) or angioplasty. Coronary stents are designed to restore blood flow by supporting the artery walls, reducing the risk of chest pain, heart attacks, and other complications associated with coronary artery disease (CAD). There are several types of coronary stents, including bare-metal stents, drug-eluting stents (DES), and bioresorbable stents, each offering unique benefits in terms of safety, efficacy, and longevity.

Coronary stents is promising, driven by advancements in stent technology, growing demand for minimally invasive procedures, and the increasing prevalence of CAD. Emerging innovations, such as bioresorbable and nanotechnology-based stents, are expected to improve long-term outcomes by reducing complications like restenosis and thrombosis. Additionally, as the aging population grows and healthcare access improves globally, particularly in developing regions, the demand for coronary stents is likely to rise, creating new growth opportunities in the market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Drive the Coronary Stent Market?

The rising prevalence of cardiovascular diseases (CVD) is significantly driving the coronary stent market, primarily due to the growing need for effective treatment options to manage and alleviate coronary artery blockages. With cardiovascular diseases causing 17.9 million deaths globally each year, according to the WHO, and coronary heart disease affecting around 18.2 million U.S. adults, as reported by the CDC, the demand for coronary stenting procedures has surged. This increasing patient pool necessitates advanced and accessible stent solutions, driving market growth as healthcare systems aim to reduce CVD-related morbidity and mortality.

The growing elderly population is indeed fueling the coronary stent market. As age is a primary risk factor for coronary artery disease, the rising number of elderly individuals directly increases the demand for coronary stents. According to the United Nations, the global population aged 65 and above is expected to reach 1.5 billion by 2050, with developing regions seeing the fastest growth. In the EU, nearly 20% of all percutaneous coronary interventions (PCIs) target patients aged 75 or older, illustrating a clear link between aging populations and increased stent procedures.

Will the High-Cost impact the Growth of the Coronary Stent Market?

The high cost of coronary stents can impact the growth of the coronary stent market. The expense of stent procedures, particularly for advanced drug-eluting stents, can be prohibitive for patients and healthcare systems, especially in low- and middle-income countries where budget constraints and limited healthcare coverage are prevalent. These costs also impact insurance premiums, making stent procedures less accessible, which can slow the adoption rate and market growth despite the increasing demand driven by aging populations and rising cardiovascular disease prevalence.

The risk of complications can impact the growth of the coronary stent market. Complications such as stent thrombosis, restenosis, and bleeding pose significant health risks, which can lead to additional procedures, increased medical costs, and patient hesitancy. Concerns over these potential complications may prompt healthcare providers to consider alternative treatments, thus limiting the market's growth despite advancements in stent technology aimed at minimizing these risks.

Category-Wise Acumens

Will the Reduced Restenosis Raise the Drug-Eluting Stents (DES) Segment for the Coronary Stent Market?

Drug-Eluting Stents (DES) Segment is dominating the coronary stent market. Reduced restenosis rates are likely to propel the growth of the Drug-Eluting Stents (DES) segment in the coronary stent market. DES is designed to release medication that inhibits cell proliferation, significantly reducing the risk of restenosis compared to bare-metal stents. This improved efficacy in preventing artery re-narrowing makes DES a preferred choice for patients and healthcare providers, driving higher adoption rates and supporting market growth in this segment.

Technological advancements are propelling the drug-eluting stents (DES) segment within the coronary stent market. Innovations such as improved biocompatible polymers, biodegradable stents, and advanced drug coatings have enhanced the safety and effectiveness of DES, reducing complications like restenosis and improving patient outcomes. These advancements make DES an increasingly preferred choice among healthcare providers, driving growth within this segment as they seek safer and more effective solutions for coronary artery disease.

Will the Proven Efficacy Fuel the Metallic Stents Segment for the Coronary Stent Market?

The metallic stents segment is ruling the coronary stent market. The proven efficacy of metallic stents is promoting growth in this segment of the coronary stent market. Metallic stents, particularly drug-eluting and bare-metal stents, have shown reliable results in maintaining vessel patency and reducing the risk of acute complications. Their durability and established clinical success make them a trusted choice for many cardiologists, especially in complex cases, driving continued demand and growth within this segment as they offer consistent and effective treatment for coronary artery disease.

Cost-effectiveness is promoting the metallic stents segment within the coronary stent market. Metallic stents, especially bare-metal stents, offer a more affordable option compared to drug-eluting or biodegradable stents, making them attractive for patients and healthcare systems in cost-sensitive regions. Their durability and relatively lower cost make metallic stents a practical choice for managing coronary artery disease, thus driving demand in regions with budget constraints or limited healthcare funding.

Country/Region-wise Acumens

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Accelerate the North American Region for Coronary Stent Market?

North America's dominance in the coronary stent market. The rising prevalence of cardiovascular diseases (CVD) is likely to accelerate the coronary stent market' in North America. With about 20.1 million adults aged 20 and older currently affected by coronary artery disease (CAD) and an expected increase to 28.5 million by 2040, there is a growing demand for coronary stents. This demand stems from the need for effective treatment options, as coronary stents play a critical role in managing CAD by improving blood flow and reducing the risk of severe cardiac events, thereby driving market growth.

The advanced healthcare infrastructure in North America is accelerating the growth of the coronary stent market. The region's extensive network of around 6,090 hospitals in the U.S. alone enables widespread access to cardiac procedures, with over 1 million coronary stent procedures performed annually. This accessibility, combined with skilled healthcare professionals and advanced medical technologies, ensures timely treatment for cardiovascular diseases, thereby driving demand and growth in the coronary stent market.

Will the Large Patient Pool Expand the Asia Pacific Region for the Coronary Stent Market?

Asia Pacific is rapidly growing in the coronary stent market due to several factors. The large patient pool in the Asia Pacific region is significantly escalating the growth of the coronary stent market. The region accounts for nearly 60% of the global cardiovascular disease burden, as reported by the Asian Pacific Society of Cardiology. Additionally, Japan's aging population, with 27.6% affected by cardiovascular diseases, highlights the demand for coronary interventions. This high prevalence, combined with the growing need for accessible treatment options, drives the expansion of the coronary stent market in Asia Pacific.

The growing disease burden is significantly escalating the coronary stent market in the Asia Pacific region. With China reporting over 330 million patients with cardiovascular diseases and India expecting its coronary artery disease cases to rise from 65.1 million to 75 million by 2030, the demand for coronary stents is increasing. This high prevalence of cardiovascular conditions is driving the need for coronary stent procedures, as healthcare providers seek effective treatments to manage the rising cases and improve patient outcomes across the region.

Competitive Landscape

The coronary stent market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the coronary stent market include:

Abbott Laboratories, Boston Scientific, Medtronic, Terumo Corporation, Braun Melsungen, Cook Medical, Biosensors International, Biotronik, Johnson & Johnson, Meril Life Sciences

Latest Developments

In April 2021, Abbott announced the launched of coronary imaging platform Ultreon 1.0 Software powered by AI in Europe. The software has been launched with an aim to improve detection of calcium-based blockages and measure vessel diameter during coronary stenting procedures.
In February 2021, Cardiovascular Systems Inc established a partnership with Chansu Vascular Technologies, LLC to produce peripheral and coronary drug-coated balloons for use in drug-eluting stents.

1 INTRODUCTION OF THE GLOBAL CORONARY STENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CORONARY STENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CORONARY STENT MARKET, BY TYPE

5.1 Overview
5.2 Bare-Metal Stents (BMS)
5.3 Drug-Eluting Stents (DES)

6 GLOBAL CORONARY STENT MARKET, BY MATERIAL TYPE

6.1 Overview
6.2 Polymer-Based Stents
6.3 Metallic Stents

7 GLOBAL CORONARY STENT MARKET, BY END USER

7.1 Overview
7.2 Cardiac Centers
7.3 Hospitals

8 GLOBAL CORONARY STENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 South Africa
- 8.6.4 Rest of Middle East and Africa

9 GLOBAL CORONARY STENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 Company Industry Footprint
9.5 Company Regional Footprint
9.6 Ace Matrix

10 COMPANY PROFILES

10.1 Abbott Laboratories
- 10.1.1 Overview
- 10.1.2 Company Insights
- 10.1.3 Business Breakdown
- 10.1.4 Product Outlook
- 10.1.5 Key Developments
- 10.1.6 Winning Imperatives
- 10.1.7 Current Focus and Strategies
- 10.1.8 Threat From Competition
- 10.1.9 Swot Analysis
10.2 Boston Scientific
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Medtronic
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Terumo Corporation
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 B. Braun Melsungen
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Cook Medical
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Biosensors International
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Biotronik, Johnson & Johnson
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Meril Life Sciences
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments